History
Gastric cancer refers to a malignant tumor that begins in the mucosa of the stomach, and throughout medical history it has long been observed as "a disease in which people waste away with indigestion and weight loss." In the West, gastric cancer accounted for a large share of cancer deaths until the early 20th century, but as hygiene and diet changed, a trend of declining incidence among younger generations appeared. In contrast, gastric cancer long remained a common cancer in East Asia, and Helicobacter pylori infection and dietary factors such as salting and smoking of foods have been cited together as the background.
The history of diagnosis and treatment is closely tied to the development of endoscopy. In the past, gastric cancer was often diagnosed by open surgery after symptoms had become severe, but as upper gastrointestinal endoscopy became widespread, confirmation by biopsy became possible and the proportion of early gastric cancers detected increased greatly. In particular, as national endoscopic screening was implemented in high-risk countries such as Japan and Korea, a pattern formed in which early diagnosis and high survival rates were observed together.
Gastrectomy was at the center of treatment, but recently, for early gastric cancers with shallow lesions and a low risk of lymph node metastasis, treatment that preserves the stomach through endoscopic resection (e.g., endoscopic submucosal dissection) has expanded. For advanced gastric cancer, as the recognition became established that surgery alone is insufficient, perioperative chemotherapy, targeted therapy, and immunotherapy were introduced, and in recent research, "precision treatment," in which drug selection differs according to the tumor's molecular markers, is expanding rapidly.
Causes
The most important causes cited for gastric cancer are factors that produce chronic gastritis and damage the gastric mucosa over a long period. The key among these is Helicobacter pylori infection. This bacterium causes persistent inflammation of the gastric mucosa and, over time, creates a pathway that can progress to gastric cancer through precancerous changes such as atrophic gastritis and intestinal metaplasia. However, not everyone infected develops gastric cancer; the bacterium's virulence factors, the host's immune response, and environmental factors such as diet and smoking act together.
Among lifestyle factors, eating salty food, a diet centered on salted, smoked, and pickled foods, smoking, heavy drinking, and obesity are observed to increase the risk. Conversely, a diet with sufficient vegetables and fruits is often reported to lower the risk. Conditions with persistent chronic inflammation of the gastric mucosa (e.g., chronic atrophic gastritis, gastric mucosal changes associated with pernicious anemia) can also increase the risk.
Genetic factors account for a portion of all gastric cancers, but there are cases with a distinct family history pattern. In particular, in hereditary syndromes associated with diffuse-type gastric cancer, even prophylactic gastrectomy may be discussed. Ultimately, it is more correct to understand the cause of gastric cancer not as "a single cause" but as the result of an interplay of infection and living conditions that create chronic inflammation, together with individual genetic vulnerability.
Genetic Epidemiology
From the perspective of genetic epidemiology, most gastric cancers occur sporadically, but there are groups that show a pattern of multiple cases within families. When several family members have gastric cancer or gastric cancer has occurred at a young age, genetic predisposition is considered more actively. A representative example is hereditary diffuse gastric cancer (HDGC), which is related to variants in a gene involved in cell-to-cell adhesion and can greatly increase the risk of gastric cancer. In such cases, there is a risk of missing the cancer with endoscopic surveillance alone, so a very strong preventive strategy, prophylactic gastrectomy, may be discussed.
However, such hereditary syndromes are a minority of all gastric cancers. The more common form is when "family history itself" raises the risk. This includes the influence of shared lifestyle habits (salty food, smoking, etc.) and Helicobacter pylori infection being similarly present within a family. Therefore, when there is a family history, it is important to plan not only genetic testing but also practical preventive measures such as checking for infection, eradication therapy, and endoscopic surveillance of precancerous lesions.
In recent research, there are increasing reports that genetic changes in the tumor, the immune environment, and viral associations (e.g., Epstein–Barr virus) can help distinguish subtypes of gastric cancer and predict treatment response. From the general public's point of view, the key point is that "family history and certain genetic diseases can raise the risk of gastric cancer, and in such cases the screening strategy changes."
General Epidemiology
Gastric cancer is a cancer with large regional variation. The burden of incidence and death is known to be high in East Asia, Central Asia, and parts of Eastern Europe, and relatively low in North America and Western Europe. It tends to be more common in men than in women, and the risk generally increases with age. Recently, however, interest has grown in some regions in gastric cancer among young people (early-onset gastric cancer), and discussion continues that its pathological types and risk factors may differ.
The prognosis of gastric cancer depends greatly on the stage (depth of invasion and presence of lymph node or distant metastasis). Early gastric cancer has good treatment outcomes, but advanced gastric cancer is complex to treat and its survival rate can be lower. It is frequently noted that in countries with systematic endoscopic screening, such as Japan and Korea, the proportion of early detection is high and overall survival rates are observed to be relatively high.
In recent research, evidence is accumulating that endoscopic screening can contribute to reducing gastric cancer deaths, and efforts are underway to make the selection of high-risk groups more precise. Because the stage at diagnosis is the key factor determining the prognosis of gastric cancer, a systematic approach to early detection is more important than anything else.
Pathogenesis
Gastric cancer can be understood as a process in which gastric mucosal cells accumulate genetic changes amid chronic inflammation and repeated injury and gradually progress through precancerous lesions to cancer. A representative pathway is the stepwise change of "chronic gastritis → atrophic gastritis → intestinal metaplasia → dysplasia → gastric cancer" that begins with Helicobacter pylori infection. In this process, inflammatory mediators, oxidative stress, and mucosal regeneration repeat, forming an environment in which mutations easily accumulate.
Histologically, gastric cancer is often understood by dividing it into intestinal and diffuse types. The intestinal type commonly goes through a relatively stepwise precancerous process, while the diffuse type tends to invade as if spreading through the stomach wall because the bonds between cells weaken, so early detection by endoscopy can be more difficult.
Recent research emphasizes that gastric cancer is a highly heterogeneous disease and that treatment response can differ according to molecular markers and the immune microenvironment. This is why targeted therapy and immunotherapy do not work equally on "all gastric cancers," and personalized treatment strategies are becoming increasingly important.
Symptoms
Gastric cancer often has no symptoms or very nonspecific symptoms in the early stage. Common symptoms are digestive symptoms such as heartburn, upper abdominal discomfort, bloating, early satiety (a feeling of fullness after eating only a little), nausea, and loss of appetite. Because these symptoms are also common in functional dyspepsia, gastritis, and gastric ulcer, it is difficult to distinguish gastric cancer by symptoms alone.
As it progresses, weight loss, persistent upper abdominal pain, vomiting, dysphagia (a feeling that food does not go down well), melena (stool that appears black due to digested blood), and fatigue due to anemia may appear. When the cancer causes bleeding, anemia can be the first clue.
When gastric cancer has spread to other organs, symptoms such as jaundice, ascites, bone pain, and difficulty breathing may accompany it. Because the early symptoms are nonspecific and difficult to distinguish from other digestive diseases, it is important to receive a precise diagnosis through endoscopy if symptoms persist.
Signs
On examination, the signs of gastric cancer are not clear in the early stage. In advanced cases, an upper abdominal mass, weight loss, pallor (anemia), abdominal distension (ascites), and lymph node enlargement may be observed. On blood tests, iron deficiency anemia can be a common clue, and if there is liver metastasis, liver function abnormalities may appear.
Imaging and endoscopic findings are central to diagnosis. On endoscopy, ulcerative lesions, elevated masses, irregular depression and hardening of the mucosa, and lesions that bleed easily may be seen. Because early gastric cancer can appear as very subtle mucosal changes, skilled endoscopic observation and supplementary techniques such as chromoendoscopy or magnifying endoscopy can be helpful.
Confirmation is made by pathological examination of tissue removed from the lesion. Because early gastric cancer can easily be missed on endoscopic findings alone, regular screening and interpretation by a skilled endoscopist are very important.
Screening
For gastric cancer screening, regional risk is very important. In countries where gastric cancer is common (e.g., Japan, Korea), national screening based on upper gastrointestinal endoscopy or upper gastrointestinal contrast radiography has been carried out. Recent studies report that endoscopic screening has high sensitivity and specificity and that an effect of reducing gastric cancer deaths has been observed.
In regions where gastric cancer is relatively rare, screening of the entire population can be difficult in terms of cost-effectiveness, so targeted screening focused on high-risk groups is discussed. High-risk groups can include people with a family history, current or past Helicobacter pylori infection, precancerous lesions such as atrophic gastritis and intestinal metaplasia, and certain population groups (such as immigrants from high-risk regions).
Recent research introduces strategies to increase the efficiency of endoscopic screening after stratifying risk with noninvasive tests such as the Helicobacter antibody test and the serum pepsinogen test. Accurately selecting high-risk groups and having them undergo endoscopic screening at appropriate intervals is the key to early detection of gastric cancer.
Diagnosis
The standard for diagnosing gastric cancer is upper gastrointestinal endoscopy and biopsy. The lesion is directly confirmed by endoscopy, and tissue is taken to confirm whether it is cancer and its histologic type. If the lesion is suspected to be early gastric cancer, the depth of invasion can be assessed with endoscopic ultrasound, or the endoscopic findings can be analyzed in detail to judge whether endoscopic treatment is possible.
After confirmation, staging is needed. Computed tomography is used to evaluate the possibility of lymph node metastasis, liver metastasis, and peritoneal metastasis. If necessary, peritoneal metastasis is also checked by positron emission tomography or diagnostic laparoscopy.
In recent research, the process of identifying molecular markers (e.g., specific growth signal receptors, immune response markers, etc.) for treatment selection is expanding, and this is particularly important in advanced gastric cancer. Accurate staging and molecular marker analysis have become essential processes for establishing the optimal treatment strategy.
Treatment
Treatment of gastric cancer depends on the stage, the patient's condition, and the location and histologic type of the tumor. For early gastric cancers with a low risk of lymph node metastasis, endoscopic resection has become established as the standard treatment. If endoscopic resection is incomplete or the risk of metastasis is high, surgical gastrectomy and lymph node dissection are needed.
In locally advanced gastric cancer, the risk of recurrence is high with surgery alone, so chemotherapy is used before and after surgery. In recent research, the optimal duration and drug combinations of adjuvant chemotherapy after surgery, as well as the role of radiation therapy in some situations, have been clarified. For metastatic gastric cancer or gastric cancer that is difficult to resect, chemotherapy is the basis, and targeted therapy and immunotherapy may be added depending on the tumor's molecular markers.
Recent studies have reported that combining immune checkpoint inhibitors with chemotherapy, and adding targeted therapy in gastric cancer positive for a specific target (e.g., human epidermal growth factor receptor 2, ERBB2), improve treatment outcomes. Personalized treatment tailored to the molecular characteristics of the tumor is becoming established as the new core direction of gastric cancer treatment.
Prognosis
The stage at diagnosis is the largest determining factor in the prognosis of gastric cancer. Early gastric cancer can be expected to be cured by endoscopy or surgery, and as the proportion of early detection increases through national screening, overall survival rates can also improve. Conversely, advanced and metastatic gastric cancers tend to have a poor prognosis, and the goal of treatment often shifts from cure to prolonging survival and controlling symptoms.
When discussing prognosis, not only survival rates but also functional changes after surgery and quality of life are important. After gastrectomy, weight loss, dumping syndrome, impaired absorption of iron and vitamins, and nutritional problems due to reduced food intake can occur, so long-term management is needed.
Recent research suggests that, with the expansion of targeted therapy and immunotherapy, survival can be prolonged in some patients, and there is an expectation that personalizing treatment based on biomarkers can increase effectiveness while reducing unnecessary toxicity. The possibility of improving the prognosis of gastric cancer is greatest when early detection and personalized treatment are combined.
Prevention
Prevention of gastric cancer can be summarized as "management of Helicobacter pylori," "surveillance of precancerous lesions," and "lifestyle improvement." Helicobacter pylori eradication therapy is regarded as one of the most important interventions for reducing the risk of developing gastric cancer. Recent research presents evidence that eradication therapy in infected people can reduce the incidence of and death from gastric cancer, and in high-risk countries, strategies that include eradication are being discussed at the public health level.
For people with confirmed precancerous lesions (atrophic gastritis, intestinal metaplasia, dysplasia), it is important not to miss early lesions through endoscopic follow-up. When there is a strong family history or a high-risk genetic disease such as hereditary diffuse gastric cancer is confirmed, even very aggressive preventive strategies may be considered on the basis of genetic counseling. For lifestyle, quitting smoking, moderating alcohol intake, reducing salt intake, eating fresh vegetables and fruits, and reducing consumption of processed, smoked, and salted foods are summarized as the recommended direction.
The most realistic key to preventing gastric cancer is "managing infection and precancerous lesions, and identifying high-risk groups so that they do not miss endoscopic screening." Maintaining an appropriate weight and regular activity also help lower overall cancer risk.